Sökning: "pharmacometrics"

Visar resultat 41 - 45 av 47 avhandlingar innehållade ordet pharmacometrics.

1. 41. Novel Pharmacometric Methods for Design and Analysis of Disease Progression Studies

   Författare :Sebastian Ueckert; Andrew C. Hooker; Mats O. Karlsson; Kayode Ogungbenro; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; pharmacometrics; optimal design; non-linear mixed effects models; degenerative diseases; Alzheimer s disease; item response theory; statistical power; Pharmaceutical Science; Farmaceutisk vetenskap;

   Sammanfattning : With societies aging all around the world, the global burden of degenerative diseases is expected to increase exponentially. From the perspective drug development, degenerative diseases represent an especially challenging class. LÄS MER

3. 42. Pharmacometric Investigations of Prediction Precision and Advances of Models for Composite Scale Data

   Författare :Gustaf Wellhagen; Maria C. Kjellsson; Bengt Hamrén; Per Olsson Gisleskog; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; pharmacometrics; modelling; non-linear mixed effects modelling; composite scale data; total score data; total score analysis; precision prediction; bounded integer; bounded integer model; IRT-informed total score analysis; item response theory-informed; mixed models for repeated measures; MMRM; dose-response; dose-response mixed models for repeated measures; DR-MMRM; HbA1c models; fit-for-purpose analysis; clinical trial analysis; Farmaceutisk vetenskap; Pharmaceutical Science;

   Sammanfattning : Clinical trials are needed to evaluate new treatments. In late-stage clinical trials, failures are mostly due to lack of efficacy. Fit-for-purpose analysis methods will likely increase the success rates and advance drug development by providing higher precision to support decisions such as go/no-go, dose selection, or sample size. LÄS MER

4. 43. Pharmacometrics Modelling in Type 2 Diabetes Mellitus : Implications on Study Design and Diabetes Disease Progression

   Författare :Siti Maisharah Sheikh Ghadzi; Maria C. Kjellsson; Mats O. Karlsson; Sandra Visser; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Pharmacometric; type 2 diabetes mellitus; impaired glucose tolerance; prediabetes; anti-diabetes drug development; insulin; glucose; natural diabetes disease progression; lifestyle intervention; short-term provocation; long-term effect; glucose homeostasis; glucose and insulin regulation; weight; dropout; Pharmaceutical Science; Farmaceutisk vetenskap; Endokrinologi och Diabetologi; Endocrinology and Diabetology;

   Sammanfattning : Pharmacometric modelling is widely used in many aspects related to type 2 diabetes mellitus (T2DM), for instance in the anti-diabetes drug development, and in quantifying the disease progression of T2DM.The aim of this thesis were to improve the design of early phase anti-diabetes drug development studies with the focus on the power to identify mechanism of drug action (MoA), and to characterize and quantify the progression from prediabetes to overt diabetes, both the natural progression and the progression with diet and exercise interventions, using pharmacometrics modelling. LÄS MER

5. 44. Pharmacometrics to improve clinical benefit assessment in oncology

   Författare :Emilie Schindler; Lena E Friberg; Mats O Karlsson; Rik de Greef; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; nonlinear mixed effect models; NONMEM; pharmacokinetics; pharmacodynamics; VEGF; SLD; targeted therapies; IRT; FDG-PET; SUVmax; Farmaceutisk vetenskap; Pharmaceutical Science;

   Sammanfattning : The high attrition rate in oncology drug development calls for new approaches that would increase the understanding of drugs’ efficacy and safety profiles. This thesis focuses on the development of pharmacometric models to characterize and quantify the relationships between drug exposure, circulating and imaging biomarkers, adverse effects, overall survival (OS), and patient-reported outcomes (PROs). LÄS MER

7. 45. Pharmacometrics to improve evaluation and individualization of anticancer drug treatment

   Författare :Sreenath Madathil Krishnan; Lena Friberg; Mats Karlsson; Zinnia Parra Gillén; Uppsala universitet; []
   Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; nonlinear mixed effect models; NONMEM; pharmacodynamics; survival modeling;

   Sammanfattning : The success rate in clinical development of newer anti-cancer molecules is the lowest compared to other major diseases. Improving the success rate and better early evaluation of efficacy of anti-cancer drugs remain challenging obstacles. LÄS MER